Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management
- PMID: 33712866
- PMCID: PMC8195939
- DOI: 10.1007/s00277-021-04485-0
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management
Abstract
Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. Primary hereditary thrombocytosis may be caused by germline mutations within the genes encoding key regulators of thrombopoiesis, i.e., thrombopoietin (THPO) and its receptor c-MPL (MPL) or the receptor's effector kinase Januskinase2 (JAK2). Furthermore, somatic mutations in JAK2, MPL, and in the gene-encoding calreticulin (CALR) have been described to act as driver mutations within the so-called Philadelphia-negative myeloproliferative neoplasms (MPNs), namely essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). Increasing knowledge on the molecular mechanisms and on the clinical complications of these diseases is reflected by the WHO diagnostic criteria and European LeukemiaNet (ELN) recommendations on the management of adult MPN. However, data on childhood thrombocytosis are rare, and no consensus guidelines for pediatric thrombocytosis exist. Current literature has highlighted differences in the epidemiology and molecular pathogenesis of childhood thrombocytosis as compared to adults. Furthermore, age-dependent complications and pharmacological specificities suggest that recommendations tailored to the pediatric population are necessary in clinical practice. Here we summarize literature on classification, diagnostics, and clinical management of childhood thrombocytosis.
Keywords: Hereditary thrombocytosis; Myeloproliferative neoplasms; Pediatrics; Platelet disorders; Thrombocytosis.
Conflict of interest statement
Clemens Stockklausner has no relevant conflict of interest to declare.
Christin Maria Duffert has no relevant conflict of interest to declare.
Holger Cario has no relevant conflict of interest to declare.
Ralf Knöfler has no relevant conflict of interest to declare.
Werner Streif has no relevant conflict of interest to declare.
Andreas Kulozik is the section editor of Pediatric Hematology of Annals of Hematology.
Figures



Similar articles
-
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607. Am J Hematol. 2017. PMID: 27991718
-
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM. Am J Clin Pathol. 2015. PMID: 25873496
-
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Am J Hematol. 2015. PMID: 25611051 Review.
-
Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.Pediatr Blood Cancer. 2016 Aug;63(8):1484-7. doi: 10.1002/pbc.26032. Epub 2016 Apr 21. Pediatr Blood Cancer. 2016. PMID: 27100794 Free PMC article.
-
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Acta Haematol. 2015. PMID: 25116092 Review.
Cited by
-
TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model.Front Oncol. 2024 Mar 22;14:1369346. doi: 10.3389/fonc.2024.1369346. eCollection 2024. Front Oncol. 2024. PMID: 38585007 Free PMC article.
-
Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.Leukemia. 2025 Jan;39(1):155-165. doi: 10.1038/s41375-024-02432-2. Epub 2024 Oct 8. Leukemia. 2025. PMID: 39375514
-
Thrombocytosis in children.Rev Assoc Med Bras (1992). 2023 May 29;69(6):e20230020. doi: 10.1590/1806-9282.20230020. eCollection 2023. Rev Assoc Med Bras (1992). 2023. PMID: 37255084 Free PMC article.
-
Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report.Exp Ther Med. 2025 Jan 16;29(3):50. doi: 10.3892/etm.2025.12800. eCollection 2025 Mar. Exp Ther Med. 2025. PMID: 39885917 Free PMC article.
-
The relationship between severity of periapical periodontitis and next-generation systemic inflammatory biomarkers in children with early childhood caries.BMC Oral Health. 2024 Sep 9;24(1):1056. doi: 10.1186/s12903-024-04842-1. BMC Oral Health. 2024. PMID: 39252035 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous